Reveal Pharmaceuticals’ Post

Thrilled to announce the participation in the Taiwan Educare Webinar on "Latest Research on Structures and Mechanisms Underlying Human Diseases & Targeting Treatment for Advanced Cancers"! 🧬 This insightful session highlights the cutting-edge advancements in medical science that are driving breakthroughs in cancer treatment and understanding the complexities of human diseases. It’s inspiring to see how innovative research is paving the way for more targeted therapies and better patient outcomes. 🌟 This session is a deep dive into cutting-edge biotechnology, AI-driven drug discovery, and genomic research that are revolutionizing how we understand complex diseases and develop targeted therapies for advanced cancers. It's incredible how technological advancements like CRISPR and machine learning are accelerating the search for more effective treatments, transforming patient care, and shaping the future of medicine. Looking forward to learning from experts and contributing to discussions that have the potential to change the future of healthcare. #CancerResearch #HealthcareAdvancements #HumanDisease #TargetedTherapies #BiomedicalScience #HealthcareFuture #ResearchAndDevelopment #TaiwanEducare #WebinarLearning

The pioneering work by the University of Wisconsin–Madison, enabling cells to be programmed for specific molecular organization, heralds a transformative era for biotechnology and CROs like ourselves. This breakthrough offers optmised control over cellular behavior, potentially revolutionising how new treatments are developed. By manipulating proteins within cells to follow designated paths, researchers can now orchestrate complex cellular functions, a leap forward in understanding and treating diseases like cancer. For the biotech industry, this means the creation of more targeted therapies with fewer side effects, significantly impacting drug discovery and development processes. CROs, pivotal in bridging innovative research and clinical applications, might see a surge in demand for bioinformatics services, as the industry seeks to leverage this tool for therapeutic innovation. This advancement underscores a future where bioinformatics and cellular engineering converge to unlock new medical treatments. #CellularEngineering #Bioinformatics #BiotechInnovation #MolecularBiology #DrugDiscovery #ProteinOrganization #MedicalResearch #TherapeuticInnovation #CancerResearch See the work here: https://lnkd.in/epGVDrpw

Insilico Medicine has unveiled a game-changing small molecule, ISM2196, designed using AI to target over 20 types of deadly cancers. Built using their Alchemistry module in Chemistry42, this molecule has demonstrated potent anti-tumor efficacy in preclinical trials. I've been a fan of founder and CEO, Dr. Alex Zhavoronkov's work for over a decade, and this achievement showcases the massive potential of AI to disrupt the traditional $3B, 10-year drug discovery process—reducing it by 10x or even 100x. We’re looking at a future of medicine that’s faster, more precise, and life-saving. As the convergence of AI with fields like biotech accelerates, it gives us renewed hope in addressing diseases resistant to today’s therapies.   This could be the beginning of a major transformation in healthcare. To read more about this and other mind-blowing breakthroughs, check out my blog post—link in the comments. How do you see AI revolutionizing healthcare in the coming decade? #AI #biotech #healthcare #cancerresearch #futureofmedicine

🌟 The future of human healing and healthcare innovation is within reach with S7 Oceanic 🌊 Investors and managers have the chance to be part of a transformative journey that will shape the landscape of regenerative medicine, disease management, and public health. 🌿 🚀 **Why Choose S7 Oceanic for Investment:** - Benefit from cutting-edge technologies like Nano Gene Chip, Stem Cell, Peptide, and Airborne COVID Nano Vaccine. - Partner with a team of dedicated researchers and scientists driving medical research forward. - Tap into a dynamic market with high demand for innovative healthcare solutions. - Contribute to global health initiatives and pandemic response efforts. 💪 🔬 **Investment Opportunities:** - Support research in regenerative medicine, personalized therapies, and vaccine development. - Explore collaborations with leading institutions and healthcare organizations. - Contribute to the growth of innovative healthcare solutions globally. 🌎 🌟💡 **Join Us in Shaping the Future of Healthcare:** Invest in S7 Oceanic to drive innovation and make a lasting impact on healthcare. Contact us today to secure your place in the future of human healing. 🌟💡🌿 📧s.massenhove@s7-oceanic.com #HealthcareInnovation #RegenerativeMedicine #InvestmentOpportunity #GlobalHealth #PandemicResponse

This article from the Wyss Institute at Harvard University retraces the evolution of CRISPR (a gene-editing technology) applications over time. While reminiscing about "early gene-editing pioneers" like George Church, Ph.D., a Core Faculty member at the Wyss Institute who has helped advance the gene editing therapy, the article also highlights crucial medical application developments, including organ transplants and sickle cell disease therapies. On March 16, 2024, a CRISPR-modified pig kidney was successfully transplanted into Richard Slayman at the Massachusetts General Hospital becoming "the first patient ever to receive an organ transplant from a pig donor"! The pig's genome was modified using CRISPR to "inactivate endogenous retroviral sequences" preventing the organs of pigs from compatibility with human patients. Learn more about other CRISPR applications and the future outlooks of the gene editing technology at the link below: https://hubs.li/Q02VbXz60

𝐂𝐀𝐑 𝐓-𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲: 𝐓𝐚𝐜𝐤𝐥𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐔𝐧𝐝𝐞𝐫 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐒𝐭𝐫𝐞𝐬𝐬 The global tumor ablation market size was estimated at USD 1.67 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2030. 📊 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 @ https://lnkd.in/grAdV5Kg Recent studies are exploring how metabolic stress impacts the efficacy of CAR T-cell therapy in cancer immunotherapy. #Metabolic stress, caused by factors such as nutrient deprivation and #hypoxia within the tumor #microenvironment, can suppress the activity of CAR T-cells, reducing their ability to target and eliminate cancer cells. Researchers are now focusing on ways to reprogram T-cell metabolism or enhance their resilience to these #stressors, aiming to improve the longevity and potency of CAR T-cell #therapies in combating tumors.  To overcome the challenges posed by metabolic stress, researchers are developing strategies such as engineering CAR T-cells with enhanced #metabolic pathways that allow them to thrive in #hostile tumor environments. Some #approaches include altering glucose and amino acid uptake mechanisms or introducing antioxidant pathways to counteract oxidative stress. 📊 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://lnkd.in/gwXpBCXi These innovations aim to increase the persistence and functionality of CAR T-cells within tumors, leading to more robust and sustained anti-cancer responses. As these approaches evolve, they hold the potential to significantly improve the effectiveness of #CAR_T- #cell_therapy, especially in solid tumors where the microenvironment is more hostile. 𝐓𝐨𝐩 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐚𝐫𝐞 European Bioinformatics Institute | EMBL-EBI | ShengTing Bioinformatics Institute | QIAGEN | Planet Pharma | Grand Valley State University | Zifo | Natera | MEDGENOME | The Jackson Laboratory | Novogene America | Excelra | SRI | Be The Match | NMDP | Axle | Dotmatics | Vasta Global | Instem | GenScript | Emmes

🔊 Weekly round-up!   💊The role of anti-viral drug development in a new pandemic era As humanity faces an impending era of pandemics, global collaboration among governments, organisations and industry is critical. In this article, epidemiologist Dr Jay Varma, SIGA Technologies, explores the urgent need for researching and developing drugs to combat a range of epidemic-prone pathogens, and reflects on the increased risk of spillovers and the challenges of vaccine limitations.   👩🏼🔬International Day of Women and Girls in Science: Jane Kendrew   We had the privilege of speaking to Dr Jane Kendrew, Director of Translational Oncology at Sygnature Discovery. With over 30 years of drug discovery experience, she shares many insights, including her inspiration to pursue a career in STEM, her achievements in the field, and how women can overcome the challenges posed to them.   🦠 Developing an effective vaccine for herpes simplex virus Researchers from the Geisel School of Medicine at Dartmouth and Thayer School of Engineering at Dartmouth have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.   🧠 Oxytocin could mitigate the progression of dementia For the first time, researchers at the Tokyo University of Science reveal the involvement of OXT in object recognition memory through the supramammillary nucleus.   Click on the links in the comments to read more! 👇   #drugdiscovery #lifescience #drugtargets 

Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) A new plasmonic and microfluidic sensing technology has been developed for the ultrasensitive and simultaneous detection of multiple biomarkers in Alzheimer's disease (AD). The platform utilizes a gold-coated fiber optic sensor and custom microfluidics to detect and differentiate different forms of amyloid beta (Aβ42) in cerebrospinal fluid (CSF). The detection limit is one order of magnitude below the clinical cut-off level, providing high sensitivity for early diagnosis of AD. The integration of the sensor with multi-channel microfluidics allows for the detection of multiple biomarkers using small sample volumes and the differentiation of biomarkers based on binding kinetics. This technology has the potential for large-scale diagnosis of diseases at an early stage.

🧬 𝗛𝗼𝘄 𝗮𝗿𝗲 #𝗟𝗡𝗣𝘀 𝗮𝗻𝗱 #𝗺𝗥𝗡𝗔 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? ◽𝗞𝗶𝗺 𝗲𝘁 𝗮𝗹. 𝗶𝗻 𝗘𝘂𝗿. 𝗝. 𝗜𝗺𝗺𝘂𝗻𝗼𝗹. (𝗟𝗶𝗻𝗸 𝗶𝗻 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀) published 16th Sep. 2024, led by Michael J Mitchell from University of Pennsylvania. ◽𝗖𝗼𝗻𝘁𝗲𝗻𝘁 This review delves into the methods and applications of LNP-based immunotherapy across five cell types: 🔹T cells 🔹NK cells 🔹Macrophages 🔹Stem cells 🔹Dendritic cells Each cell type offers significant potential in immunotherapy but also presents unique challenges and delivery obstacles. ◽ 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹 𝗼𝘂𝘁𝗹𝗼𝗼𝗸 The reprogramming of immune cells using LNPs (transient, in vivo) instead of lentiviral (permanent, ex vivo) approaches is advancing. Companies like Capstan and Orbital are leading the clinical advancement of LNP-based CAR T approaches. Will the transient nature of mRNA-transfected CAR T cells provide durability or is the long-term persistence of lentiviral transformations needed? ◽ 𝗚𝗲𝗻𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 ｜ 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗡𝗲𝘄𝘀 Follow me for more breaking research & news.

Google DeepMind Unveils AlphaProteo: A Breakthrough in Protein Design DeepMind has introduced AlphaProteo, an AI system capable of designing novel protein binders that target specific molecules. This advancement has the potential to transform drug development and disease research. Trained on vast protein datasets, AlphaProteo outperforms traditional methods with significantly higher binding affinities—up to 300 times better in some cases. The system has successfully targeted proteins associated with cancer, inflammation, and viral infections, although it has limitations, such as with TNFɑ. AlphaProteo could accelerate advancements across biotechnology, from drug development to agriculture. here's the link for detailed read: https://lnkd.in/gvjJxQcz #Google #DeepMind #AlphaProteo